# Safety and Efficacy of Pegylated Exenatine Injection (PB-119) in Drug-naïve T2DM Subjects

Study · id `cardio:ct-nct04504370` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04504370](<https://clinicaltrials.gov/study/NCT04504370>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04504370

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 273 participants.

## Technical summary

Registry record NCT04504370. Randomized; quadruple masking; primary purpose treatment. Start 2020-04-27 (actual); primary completion 2022-03-30 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 273 participants (enrolled count; ClinicalTrials.gov record NCT04504370, source copy `cardio:ctgov-nct04504370-2023-07-28`, retrieved 2026-10-26)
- Started: 2020-04-27 (actual) (ClinicalTrials.gov record NCT04504370, source copy `cardio:ctgov-nct04504370-2023-07-28`, retrieved 2026-10-26)
- Primary completion: 2022-03-30 (actual) (ClinicalTrials.gov record NCT04504370, source copy `cardio:ctgov-nct04504370-2023-07-28`, retrieved 2026-10-26)
- Completion: 2022-11-28 (actual) (ClinicalTrials.gov record NCT04504370, source copy `cardio:ctgov-nct04504370-2023-07-28`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT04504370, source copy `cardio:ctgov-nct04504370-2023-07-28`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04504370-2023-07-28`, retrieved 2026-10-26)

## The registry's words

- Brief title: Safety and Efficacy of Pegylated Exenatine Injection (PB-119) in Drug-naïve T2DM Subjects
- Acronym: PB119
- Condition: Type 2 Diabetes Mellitus (T2DM)
- Intervention (Drug): GLP-1 receptor agonist
- Intervention (Drug): Placebo
- Lead sponsor: PegBio Co., Ltd.
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record once doses, forms and salt words are removed: GLP-1 receptor agonists (drug class) (`cardio:glp1-receptor-agonists`)
- Registry lists this organization as the lead sponsor: PegBio Co., Ltd. (`cardio:org-pegbio-co-ltd`)

## Provenance

Content hash: d8c4175b289411fe8edbd91d64406b5f98b597b011b93edc6b9ae1633946c38d
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
